The indicator of osteogenesis is a potential marker of the risk of cardiovascular diseases in patients with type 2 diabetes mellitus

Autor: A.V. Кovalchuk, O.V. Zinych, N.M. Kushnarоva, V.M. Kovalchuk, O.V. Prybyla, K.O. Shyshkan-Shyshova

Publikováno v: Mìžnarodnij Endokrinologìčnij Žurnal, Vol 20, Iss 4, Pp 286-291 (2024)

Background. An increase in mortality due to cardiovascular diseases in patients with diabetes mellitus necessitates the search for effective prevention and treatment strategies. Osteocalcin, a proven marker of bone metabolism playing a key role in th

Externí odkaz: https://doaj.org/article/fafaa058b11846cb997c8acd10e43740

Functional activity of the adrenal glands in type 2 diabetes patients with different hormonal and metabolic phenotypes

Autor: O.V. Prybyla, O.V. Zinych, N.M. Kushnarova, A.V. Kovalchuk, K.O. Shyshkan-Shyshova

Publikováno v: Mìžnarodnij Endokrinologìčnij Žurnal, Vol 19, Iss 2, Pp 94-99 (2023)

Background. Clinical trials showed a number of additional phenotypes of metabolic syndrome. All of them differ in the type of metabolic disorders and the composition of subcutaneous and visceral adipose tissue. Some of phenotypes have a number of cli

Externí odkaz: https://doaj.org/article/ba0688afbee94580b152db7215a55cee

Decrease in the efficacy of glucagon-like peptide-1 receptor agonists: what is the reason?

Autor: N.M. Kushnarova, O.V. Zinych, V.V. Korpavchev, A.V. Kovalchuk, O.V. Prybyla, K.O. Shyshkan-Shishova

Publikováno v: Mìžnarodnij Endokrinologìčnij Žurnal, Vol 17, Iss 8, Pp 637-645 (2021)

The review deals with the drugs of a group of glucagon-like peptide-1 receptors agonists (GLP-1RA) the action of which is based on the incretin effect. In addition to insulinotropic and glucagonostatic action, GLP-1RA contributes to the improvement o

Externí odkaz: https://doaj.org/article/1d6446a88c4b46c195dea5739b20376a

Effect of probiotics and incretine mimeticss on the levels of glucagon-like peptide-1 in blood serum of patients with type 2 diabetes mellitus

Autor: K.A. Shyshkan-Shyshova, O.V. Zinych, N.M. Kushnareva, A.V. Кovalchuk, O.V. Prybyla

Publikováno v: Mìžnarodnij Endokrinologìčnij Žurnal, Vol 17, Iss 8, Pp 604-612 (2021)

Background. Type 2 diabetes mellitus is characterized by a violation of the incretin effect, in particular a decrease in the secretion of glucagon-like peptide-1 (GLP-1) by intestinal endothelial cells. In recent decades, the intestinal microbiota ha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9af6fcde521062052d1c3d25254c100c
https://doi.org/10.22141/2224-0721.17.8.2021.246792

Фармакокінетичні характеристики й морфометричні ефекти інгібіторів натрійзалежних котранспортерів глюкози 2 в чоловіків і жінок, хворих на цукровий діабет 2-го типу (огляд літератури й власні результати)

Autor: O.V. Prybyla

Publikováno v: INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine); Vol. 17 No. 4 (2021); 293-303
Международный эндокринологический журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 17 № 4 (2021); 293-303
Міжнародний ендокринологічний журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 17 № 4 (2021); 293-303
Mìžnarodnij Endokrinologìčnij Žurnal, Vol 17, Iss 4, Pp 293-303 (2021)

Background. According to the latest international clinical guidelines, gliflozins — sodium-glucose cotransporter-2 inhibitors — are indicated as oral antidiabetic drugs of second-third-line therapy in type 2 diabetes mellitus. Due to insulin-inde

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e05600f8816b02b3bb55207af4ac6e9
https://doi.org/10.22141/2224-0721.17.4.2021.237342